IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology

May 01, 2019

SAINT LAURENT, Quebec, May 01, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,272,038 entitled “Film Dosage Form with Extended Release Mucoadhesive Particles.” The patent covers the design and manufacturing of topical oral films (“TOF”) for the local (topical) treatment of diseases of the oral mucosa using mucoadhesive particles.

This patent is in the same family as U.S. Patent 9,668,970 – issued to IntelGenx in June 2017 – and provides broader coverage for IntelGenx’s proprietary technology, which is intended to provide sustained release of an active agent to a target area of the oral cavity. The technology is useful for the topical treatment of oral diseases and conditions such as gingivitis, buccal ulcers, canker sores, Sjögren’s syndrome, oral mucositis and Behcet’s disease.

“This is the second orange book eligible U.S patent IntelGenx has been granted for our topical oral film technology, and it reflects our strategy to broaden and diversify our intellectual property portfolio to obtain protection for the many applications of our VersaFilm® technology,” said Horst G. Zerbe, CEO of IntelGenx. “In this case, we believe our technology offers a novel and potentially superior treatment option for oral diseases such as Sjögren’s syndrome and oral mucositis, both of which represent significant unmet medical need and a large market opportunity.”

The market opportunity for treatments of oral disease and conditions is large and growing. For example, available data indicate that the global market for oral mucositis treatments is approximately USD$2 billion, and is expected to grow at a compound annual rate of approximately 7% through to 2024, while the global Sjögren’s syndrome market is expected to reach USD$2 billion by 2024.

About IntelGenx Topical Oral Film

IntelGenx’s TOF has a unique mode of action. It facilitates the controlled release of an active agent to the buccal cavity and its transport through the oral mucosa, while avoiding the discomfort often associated with conventional long lasting mucoadhesive films or tablets. The controlled release of an active agent for local action in the buccal cavity is achieved by providing an oral film in which small sized mucoadhesive particles containing the active agent are dispersed in a disintegrating film matrix. Upon administration in the oral cavity, the film quickly disintegrates and releases the mucoadhesive particles which will bind to the oral mucosa. The active agent can be released from the mucoadhesive particles over a prolonged period of time as the mucoadhesive material slowly dissolves or erodes.

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm® and VetaFilm™ technology platforms.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, which was established for oral film technology platforms, offers by supporting lab-scale to pilot- and commercial-scale production. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp. 

For IntelGenx

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com

Or

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

IGX Logo Medium Size.jpg

Source: IntelGenx Technologies Corp.